Navigation Links
Patent for Making Combination Chemotherapy Work Better
Date:3/24/2009

SAN JOSE, Calif., March 24 /PRNewswire/ -- Patent 7,507,704 issued on 03/24/09 to NexGen Biomedical, Inc. founder Mark Zamoyski of San Jose, California discloses an improved method of treating lung, brain, pancreatic, breast and colon cancers that are driven by a mutation known as HER1 overexpression (also called EGFR or c-ErbB-1). The patent presents a case for why today's concurrent HER1 blocker / S-Phase cytotoxic protocols achieve only a fraction of the potential inherent in the combination of the underlying drugs. Novel synergistic protocols are provided.

All proliferating cells progress through 4 distinct phases, in sequence, G1, S, G2, and M. "S-Phase cytotoxics, such as Pfizer's irinotecan or Eli Lilly's gemcitabine, are capable of killing virtually all cells that are in the S-Phase, however, less than one third of cancer cells are typically in the S-Phase during chemotherapy," explains Mark Zamoyski, the inventor. "Mechanistically, HER1 blockers, such as Genentech's erlotinib, AstraZeneca's gefitinib, ImClone's cetuximab and Amgen's panitumumab arrest and aggregate HER1 overexpressing cancer cells in the G1-Phase. This results in S-Phase depletion, greatly reducing the number of cancer cells killed by the S-Phase cytotoxic." The patent provides a crucial modification to the protocols by adding existing drugs to provide S-Phase enrichment at the appropriate time, while using the HER1 blocker to inhibit tumor regrowth between administrations of S-Phase cytotoxic.

Patent 7,507,704 is the third in a series of patents awarded to Mr. Zamoyski for cancer specific S-Phase enrichment relative to administrations of S-Phase cytotoxic chemotherapy. "With less than one third of cancer cells in the S-Phase, today's cytotoxic protocols only extend life expectancy by a few months. Doubling the number of cancer cells in the S-Phase would provide a way of indefinitely keeping most cancers in check. Tripling the number, while simultaneously preventing tumor regrowth between administrations of S-Phase cytotoxic, is required under established principles of chemotherapy for curative outcome. Drugs capable of doing both already exist for many cancers, providing the potential for an immediate advance in cancer treatment under our protocols," according to Mr. Zamoyski. Richard Lepidi, NexGen's business advisor, concludes "The IP has now reached a critical mass that allows us to pursue business collaborations for clinical development of the technology."

More information is available at www.nexgen.biz under Cell Cycle Synchronous Chemotherapy.


'/>"/>
SOURCE NexGen Biomedical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Confirmation of Bogoch Replikins Influenza Patents by Harvard-CDC and Scripps-Crucell Data
2. Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent
3. Intradigm Receives Notice of Allowance for Key RNA Interference (RNAi) Patent Covering Potent siRNA Sequence
4. Shire Files Lawsuit Against Barr Laboratories for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patents
5. VIASPACE Granted US Patent
6. InNexus Biotechnology Announces New Patents Protecting Novel Cell Penetrating DXL(TM) Antibodies
7. VIA Pharmaceuticals Announces Grant of New Patent on Lead Compound VIA-2291
8. Mindset BioPharmaceuticals (USA) Inc Obtains Notice of Allowance for European Patent Related to Use of Insulin Sensitizers in Senile Dementia, Dementia and Memory Loss
9. InterMune Announces Issuance of U.S. Patent for ITMN-191
10. Odyssey Thera Granted U.S. Patent for Novel GPCR Assay Strategy
11. Vermillion Announces Notice of Issuance of U.S. Patent Covering Hepcidin as a Biomarker for Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... discussions on a range of subjects including policies, debt and ... Poloz. Speaking at a lecture to the Canadian ... to the country,s inflation target, which is set by both ... "In certain areas there needs to be ... why not sit down and address strategy together?" ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... pleased to announce the launch of their brand, UP4™ Probiotics, into Target stores ... 35 years, is proud to add Target to its list of well-respected retailers. ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. ... test has received AOAC Research Institute approval 061601. , “This is another AOAC-RI ... stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate ...
(Date:6/23/2016)... ... ... STACS DNA Inc., the sample tracking software company, today announced that Dr. ... STACS DNA as a Field Application Specialist. , “I am thrilled that Dr. ... STACS DNA. “In further expanding our capacity as a scientific integrator, Hays brings a ...
Breaking Biology Technology:
(Date:6/16/2016)... 16, 2016 The global ... to reach USD 1.83 billion by 2024, according ... Inc. Technological proliferation and increasing demand in commercial ... to drive the market growth.      ... The development of advanced multimodal techniques for biometric ...
(Date:6/7/2016)... TORONTO , June 7, 2016  Syngrafii ... begun a business relationship that includes integrating Syngrafii,s ... pilot branch project. This collaboration will result in ... for the credit union, while maintaining existing document ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
(Date:6/2/2016)... 2016 Perimeter Surveillance & Detection ... Physical Infrastructure, Support & Other Service  The ... offers comprehensive analysis of the global Border Security ... revenues of $17.98 billion in 2016. Now: ... leader in software and hardware technologies for advanced video ...
Breaking Biology News(10 mins):